EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions

Zhehan Diao, Yun Wang, Shukun Mu, Xiaofeng Wu, Suchun Yu, Zhongming Wang

Frontiers in Oncology · 19.03.2026 · 16

DOI: 10.3389/fonc.2026.1756245 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 19.03.2026. Verfasst von Zhehan Diao und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China. Die Arbeit nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) continues to rise in incidence and remains one of the deadliest solid tumors due to its insidious onset and extremely poor overall survival. Current therapeutic options—surgery, chemotherapy, and radiotherapy—offer limited benefit for most patients, largely because of the tumor’s dense stromal architecture, profoundly immunosuppressive microenvironment, and inherent resistance to conventional treatments. In recent years, advances in immune checkpoint inhibitors (ICIs), cancer vaccines, oncolytic viruses, and adoptive cell therapies have driven steady progress in the field of PDAC immunotherapy. At the same time, multimodal strategies that combine immunotherapy with radiotherapy, targeted agents, or chemotherapy have begun to show promising synergistic activity. This review summarizes the recent developments in both single-agent and combination immunotherapeutic approaches for PDAC, and highlights the key challenges and future directions for improving treatment outcomes.

Schlagwörter

Stichwörter der Autor:innen

Pancreatic ductal adenocarcinomacancer vaccinesimmune checkpoint inhibitorsimmunotherapy combination strategiestumor microenvironment; radiotherapy

Autor:innen und Institutionen

  • School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
  • Department of Radiation Oncology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
  • Department of Pharmacy, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.

Zitieren

APA

Diao, Z., Wang, Y., Mu, S., Wu, X., Yu, S., & Wang, Z. (2026). Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1756245

Vancouver

Diao Z, Wang Y, Mu S, Wu X, Yu S, Wang Z. Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1756245

BibTeX
@article{Diao2026,
  author = {Diao, Zhehan and Wang, Yun and Mu, Shukun and Wu, Xiaofeng and Yu, Suchun and Wang, Zhongming},
  title = {Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1756245}
}
Kostenlos starten →